XML 27 R12.htm IDEA: XBRL DOCUMENT

Expenses

12 Months Ended

Jun. 30, 2022

Text block [abstract]

Expenses

Note 7. Expenses


		Consolidated
		2022				2021				2020
		A$’000				A$’000				A$’000

Loss before income tax includes the following specific

Research and development

EVT-801 program costs			2,520				1,073				—
Cantrixil program costs			12				429				1,673
Paxalisib program costs			13,713				11,404				5,801
Employee benefits expense - salaries & wages and staff benefits			1,664				336				861
- superannuation			25				26				43
- share based payments			365				8				32
Total research & development (excluding amortisation)			18,299				13,276				8,410

Amortisation
Paxalisib licensing agreement			1,084				1,084				1,084
Evotech licensing agreement			869				181				—

Total amortisation			1,953				1,265				1,084

Total research & development			20,252				14,541				9,494

Net foreign exchange loss
Net foreign exchange loss			—				430				—

Rental expense relating to operating leases
Minimum lease payments			73				93				108

Superannuation expense
Defined contribution superannuation expense			138				138				140

Employee benefits expense G&A
- salaries & wages and staff benefits			1,674				1,011				1,078
- superannuation			129				112				96
- share based payments			1,310				552				230
Total employee benefits expense G&A			3,113				1,675				1,404

Other Expenses
Chinese With-Holding Tax incurred on license transaction			—				931				—
Chinese Value Added Tax incurred on license transaction			—				538				—

			—				1,469				—